Literature DB >> 29666280

LSD1: A single target to combat lineage plasticity in lethal prostate cancer.

Leigh Ellis1,2,3, Massimo Loda1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29666280      PMCID： PMC5939118          DOI： 10.1073/pnas.1804205115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  15 in total

1.  Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.

Authors:  Changmeng Cai; Housheng Hansen He; Sen Chen; Ilsa Coleman; Hongyun Wang; Zi Fang; Shaoyong Chen; Peter S Nelson; X Shirley Liu; Myles Brown; Steven P Balk
Journal:  Cancer Cell       Date:  2011-10-18       Impact factor: 31.743

2.  A basal stem cell signature identifies aggressive prostate cancer phenotypes.

Authors:  Bryan A Smith; Artem Sokolov; Vladislav Uzunangelov; Robert Baertsch; Yulia Newton; Kiley Graim; Colleen Mathis; Donghui Cheng; Joshua M Stuart; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-12       Impact factor: 11.205

3.  EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.

Authors:  Kexin Xu; Zhenhua Jeremy Wu; Anna C Groner; Housheng Hansen He; Changmeng Cai; Rosina T Lis; Xiaoqiu Wu; Edward C Stack; Massimo Loda; Tao Liu; Han Xu; Laura Cato; James E Thornton; Richard I Gregory; Colm Morrissey; Robert L Vessella; Rodolfo Montironi; Cristina Magi-Galluzzi; Philip W Kantoff; Steven P Balk; X Shirley Liu; Myles Brown
Journal:  Science       Date:  2012-12-14       Impact factor: 47.728

4.  The Polycomb group protein EZH2 directly controls DNA methylation.

Authors:  Emmanuelle Viré; Carmen Brenner; Rachel Deplus; Loïc Blanchon; Mario Fraga; Céline Didelot; Lluis Morey; Aleyde Van Eynde; David Bernard; Jean-Marie Vanderwinden; Mathieu Bollen; Manel Esteller; Luciano Di Croce; Yvan de Launoit; François Fuks
Journal:  Nature       Date:  2005-12-14       Impact factor: 49.962

5.  Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).

Authors:  Jonathan Welti; Adam Sharp; Wei Yuan; David Dolling; Daniel Nava Rodrigues; Ines Figueiredo; Veronica Gil; Antje Neeb; Matthew Clarke; George Seed; Mateus Crespo; Semini Sumanasuriya; Jian Ning; Eleanor Knight; Jeffrey C Francis; Ashley Hughes; Wendy S Halsey; Alec Paschalis; Ram S Mani; Ganesh V Raj; Stephen R Plymate; Suzanne Carreira; Gunther Boysen; Arul M Chinnaiyan; Amanda Swain; Johann S de Bono
Journal:  Clin Cancer Res       Date:  2018-03-19       Impact factor: 12.531

6.  LSD1 activates a lethal prostate cancer gene network independently of its demethylase function.

Authors:  Archana Sehrawat; Lina Gao; Yuliang Wang; Armand Bankhead; Shannon K McWeeney; Carly J King; Jacob Schwartzman; Joshua Urrutia; William H Bisson; Daniel J Coleman; Sunil K Joshi; Dae-Hwan Kim; David A Sampson; Sheila Weinmann; Bhaskar V S Kallakury; Deborah L Berry; Reina Haque; Stephen K Van Den Eeden; Sunil Sharma; Jared Bearss; Tomasz M Beer; George V Thomas; Laura M Heiser; Joshi J Alumkal
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-26       Impact factor: 11.205

Review 7.  Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.

Authors:  X Yuan; C Cai; S Chen; S Chen; Z Yu; S P Balk
Journal:  Oncogene       Date:  2013-06-10       Impact factor: 9.867

8.  Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.

Authors:  Ana M Aparicio; Li Shen; Elsa Li Ning Tapia; Jing-Fang Lu; Hsiang-Chun Chen; Jiexin Zhang; Guanglin Wu; Xuemei Wang; Patricia Troncoso; Paul Corn; Timothy C Thompson; Bradley Broom; Keith Baggerly; Sankar N Maity; Christopher J Logothetis
Journal:  Clin Cancer Res       Date:  2015-11-06       Impact factor: 12.531

9.  Polycomb-mediated silencing in neuroendocrine prostate cancer.

Authors:  Pier-Luc Clermont; Dong Lin; Francesco Crea; Rebecca Wu; Hui Xue; Yuwei Wang; Kelsie L Thu; Wan L Lam; Colin C Collins; Yuzhuo Wang; Cheryl D Helgason
Journal:  Clin Epigenetics       Date:  2015-04-03       Impact factor: 6.551

10.  BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer.

Authors:  Irfan A Asangani; Kari Wilder-Romans; Vijaya L Dommeti; Pranathi M Krishnamurthy; Ingrid J Apel; June Escara-Wilke; Stephen R Plymate; Nora M Navone; Shaomeng Wang; Felix Y Feng; Arul M Chinnaiyan
Journal:  Mol Cancer Res       Date:  2016-01-20       Impact factor: 5.852
View more
  6 in total

Review 1.  Epigenetic reprogramming during prostate cancer progression: A perspective from development.

Authors:  Sakshi Goel; Vipul Bhatia; Tanay Biswas; Bushra Ateeq
Journal:  Semin Cancer Biol       Date:  2021-02-02       Impact factor: 17.012

Review 2.  LSD1/KDM1A inhibitors in clinical trials: advances and prospects.

Authors:  Yuan Fang; Guochao Liao; Bin Yu
Journal:  J Hematol Oncol       Date:  2019-12-04       Impact factor: 17.388

Review 3.  Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment.

Authors:  Tomoyuki Makino; Kouji Izumi; Atsushi Mizokami
Journal:  Biomedicines       Date:  2021-04-12

Review 4.  Histone Methylases and Demethylases Regulating Antagonistic Methyl Marks: Changes Occurring in Cancer.

Authors:  Joyce Taylor-Papadimitriou; Joy M Burchell
Journal:  Cells       Date:  2022-03-25       Impact factor: 6.600

5.  OCT1-target neural gene PFN2 promotes tumor growth in androgen receptor-negative prostate cancer.

Authors:  Daisuke Obinata; Daigo Funakoshi; Kenichi Takayama; Makoto Hara; Birunthi Niranjan; Linda Teng; Mitchell G Lawrence; Renea A Taylor; Gail P Risbridger; Yutaka Suzuki; Satoru Takahashi; Satoshi Inoue
Journal:  Sci Rep       Date:  2022-04-12       Impact factor: 4.379

6.  Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.

Authors:  W Nathaniel Brennen; Yezi Zhu; Ilsa M Coleman; Susan L Dalrymple; Lizamma Antony; Radhika A Patel; Brian Hanratty; Roshan Chikarmane; Alan K Meeker; S Lilly Zheng; Jody E Hooper; Jun Luo; Angelo M De Marzo; Eva Corey; Jianfeng Xu; Srinivasan Yegnasubramanian; Michael C Haffner; Peter S Nelson; William G Nelson; William B Isaacs; John T Isaacs
Journal:  JCI Insight       Date:  2021-04-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.